Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter ...
Bausch + Lomb Corporation , a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGilitytm Inserter preloaded IOL ...
Zacks Investment Research on MSN
Bausch + Lomb launches EyeGility inserter for enVista IOLs in the US
Bausch + Lomb BLCO recently announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery ...
Hosted on MSN
Bausch + Lomb raises 2025 revenue guidance to $5.15B as dry eye and contact lens growth accelerate
CEO Brenton L. Saunders reported "our constant currency revenue growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions ...
When it comes to refractive surgery, not all patients are created equal. A 28-year-old patient with myopia desiring to be ...
Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital ...
This summer, Bausch + Lomb unveiled plans to acquire a dry eye disease treatment from Novartis for up to $2.5 billion. Now, the eye health company has closed the deal. The purchase of XIIDRA, a 5% a ...
Bausch + Lomb announced topline results from its phase 2 study of BL1107 in patients with glaucoma. According to the company, ...
Bausch + Lomb will stop developing a topical eye drop for glaucoma after the drug failed to meet its primary endpoint in a phase 2 study. The company on Thursday said the drug, BL1107, didn't ...
Among dry eye sufferers who said their stress or anxiety levels were affected, most (73%) reported improvement following treatment While some sufferers (22%) were aware that dry eye symptoms could be ...
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results